Clinical Trials in New York

Showing 12221-12240 of 22,668 trials

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

NCT01529268

CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate delayed-release capsules will result in improvement in liver disease severity.

Nonalcoholic Fatty Liver Disease (NAFLD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)169 participantsStarted Jun 2012

San Diego, California, United States • San Francisco, California, United States • Atlanta, Georgia, United States +7 more locations

COMPLETEDPhase 2< 1 mile

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

NCT01470469

This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.

Generalized Anxiety Disorder (GAD)Anxiety, SeparationPhobia, Social

Shire83 participantsStarted Jan 2012

Birmingham, Alabama, United States • Carson, California, United States • Imperial, California, United States +30 more locations

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Find Trials by Condition in New York

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

World Trade Center Kidney-Link

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment

Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Local Vasoconstriction in Postural Tachycardia Syndrome

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17